ACZONE 7.5% Rx
Generic Name and Formulations:
Dapsone 7.5%; gel.
Indications for ACZONE 7.5%:
Wash skin and pat dry. Apply pea-sized amount to entire face or other affected area in a thin layer once daily. Rub in gently and completely. Wash hands after use. Reevaluate if no improvement after 12 weeks.
Avoid in congenital or idiopathic methemoglobinemia. G6PD deficiency: may have increased risk of methemoglobinemia or hemolytic anemia; discontinue if occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Increased risk of hemolysis in G6PD-deficient patients with concomitant trimethoprim/sulfamethoxazole, other folic acid antagonists (eg, pyrimethamine), anticonvulsants, rifampin, St. John's wort. Increased risk of methemoglobinemia with concomitant sulfonamides, acetaminophen, chloroquine, nitrates, nitrites, nitrofurantoin, phenobarbital, phenytoin, primaquine, quinine, and others. Skin/hair discoloration with topical benzoyl peroxide.
Application site reactions (oiliness, peeling, dryness, erythema, pruritus).
Gel 5% (tubes)—60g, 90g; Gel 7.5% (pumps)—30g, 60g, 90g
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation